Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:56 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 1RecruitingINTERVENTIONAL

Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)

ClinicalTrials.gov · NCT07908316 · Registry updated: 2026-11-02

Condition / research focus: Obesity; Overweight
Sponsor: Amgen
Countries with listed sites: United States
Registry dates and results: Start: 2026-11-13. Completion: 2028-02-25 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Maridebart cafraglutide (drug) — also listed as: AMG 133, MariTide

Where the study takes place — 9 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Arizona Research Center
Phoenix, Arizona, United States
Site recruitment: Recruiting
Catalina Research Institute LLC (CRI) - Montclair
Montclair, California, United States
Site recruitment: Recruiting
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, United States
Site recruitment: Recruiting
AGA Clinical Trials
Hialeah, Florida, United States
Site recruitment: Recruiting
K2 Medical Research Orlando
Maitland, Florida, United States
Site recruitment: Recruiting
The Alliance for Multispecialty Research - Lexington
Lexington, Kentucky, United States
Site recruitment: Recruiting
Alliance for Multispecialty Research - Knoxville
Knoxville, Tennessee, United States
Site recruitment: Recruiting
Fortrea Clinical Research Unit - Dallas
Dallas, Texas, United States
Site recruitment: Recruiting
Fortrea Clinical Research Unit Inc. - Madison
Madison, Wisconsin, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2Not yet recruitingINTERVENTIONAL

Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer

ClinicalTrials.gov · NCT07909889 · Registry updated: 2026-11-02

Condition / research focus: Breast Cancer (Early Breast Cancer); Obesity
Sponsor: Aarhus University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2027-03. Completion: 2029-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (Wegovy®) (drug) — also listed as: Wegovy

Where the study takes place — 2 listed sites

Department of Oncology, Aarhus University Hospital
Aarhus N, Denmark
Site recruitment: Not reported
Department of Oncology, Aarhus University Hospital
Aarhus N, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3Not yet recruitingINTERVENTIONAL

Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea

ClinicalTrials.gov · NCT07846865 · Registry updated: 2026-11-02

Condition / research focus: Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive
Sponsor: Woolcock Institute of Medical Research
Countries with listed sites: Australia
Registry dates and results: Start: 2026-10-01. Completion: 2028-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Continuous Positive Airway Pressure (device)
Tirzepatide (drug)

Where the study takes place — 1 listed sites

Woolcock Institute of Medical Research
Macquarie Park, New South Wales, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2Active, not recruitingINTERVENTIONAL

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT06700538 · Registry updated: 2026-10-30

Condition / research focus: Obesity
Sponsor: Arrowhead Pharmaceuticals
Countries with listed sites: Australia · Canada · Georgia · New Zealand
Registry dates and results: Start: 2024-12-04. Completion: 2028-02-15 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ARO-INHBE (drug)
Placebo (drug)
Tirzepatide (drug)

Where the study takes place — 15 listed sites

Research Site
Camberwell, Australia
Site recruitment: Not reported
Research Site
Charlestown, Australia
Site recruitment: Not reported
Research Site
Maroochydore, Australia
Site recruitment: Not reported
Research Site
Sydney, Australia
Site recruitment: Not reported
Research Site
Chicoutimi, Canada
Site recruitment: Not reported
Research Site
Concord, Canada
Site recruitment: Not reported
Research Site
Toronto, Canada
Site recruitment: Not reported
Research Site
Tbilisi, Georgia
Site recruitment: Not reported
Research Site 2
Tbilisi, Georgia
Site recruitment: Not reported
Research Site
Tbilisi, Georgia
Site recruitment: Not reported
Research Site
Tbilisi, Georgia
Site recruitment: Not reported
Research Site
Grafton, Auckland, New Zealand
Site recruitment: Not reported
Research Site
Auckland, New Zealand
Site recruitment: Not reported
Research Site
Auckland, New Zealand
Site recruitment: Not reported
Research Site
Christchurch, New Zealand
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4Active, not recruitingINTERVENTIONAL

Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

ClinicalTrials.gov · NCT06774079 · Registry updated: 2026-10-29

Condition / research focus: Crohn Disease
Sponsor: University of Miami
Countries with listed sites: United States
Registry dates and results: Start: 2025-03-05. Completion: 2027-03-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)
Mediterranean diet (behavioral)

Where the study takes place — 1 listed sites

University of Miami
Miami, Florida, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients

ClinicalTrials.gov · NCT07728318 · Registry updated: 2026-10-29

Condition / research focus: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Sponsor: Akhtar Saeed Medical and Dental College
Countries with listed sites: No country reported
Registry dates and results: Start: 2027-12-12. Completion: 2028-05-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide + Standard Therapy (Intervention Group) (other)
Standard Oral Antidiabetic Drugs (OADs) (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2Active, not recruitingINTERVENTIONAL

An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder

ClinicalTrials.gov · NCT07693608 · Registry updated: 2026-10-29

Condition / research focus: Obesity; Methamphetamine Use Disorder; Cocaine Use Disorder; Stimulant Use Disorders
Sponsor: University of Texas Southwestern Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2026-08-19. Completion: 2030-03-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)

Where the study takes place — 1 listed sites

UT Southwestern Medical Center
Dallas, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity

ClinicalTrials.gov · NCT07504172 · Registry updated: 2026-10-28

Condition / research focus: Overweight , Obesity; Obesity (Disorder)
Sponsor: Radboud University Medical Center
Countries with listed sites: Netherlands
Registry dates and results: Start: 2026-04-01. Completion: 2026-10-14 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Mounjaro

Where the study takes place — 10 listed sites

NOK clinics
Amsterdam, Netherlands
Site recruitment: Not reported
NOK clinics
Arnhem, Netherlands
Site recruitment: Not reported
NOK clinics
Beverwijk, Netherlands
Site recruitment: Not reported
NOK clinics
Gouda, Netherlands
Site recruitment: Not reported
NOK clinics
Heerlen, Netherlands
Site recruitment: Not reported
NOK clinics
Hoogeveen, Netherlands
Site recruitment: Not reported
NOK clinics
Nieuwegein, Netherlands
Site recruitment: Not reported
NOK clinics
Terneuzen, Netherlands
Site recruitment: Not reported
NOK clinics
The Hague, Netherlands
Site recruitment: Not reported
NOK clinics
Venlo, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Mechanisms of Weight Loss: Tirzepatide vs Semaglutide

ClinicalTrials.gov · NCT07900074 · Registry updated: 2026-10-28

Condition / research focus: Obesity (Disorder)
Sponsor: McMaster University
Countries with listed sites: Canada
Registry dates and results: Start: 2026-10-31. Completion: 2029-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)
Semaglutide (drug)

Where the study takes place — 1 listed sites

McMaster University
Hamilton, Ontario, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2Not yet recruitingINTERVENTIONAL

The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

ClinicalTrials.gov · NCT05499702 · Registry updated: 2026-10-28

Condition / research focus: Type2diabetes
Sponsor: Adrian Vella
Countries with listed sites: United States
Registry dates and results: Start: 2027-12-15. Completion: 2029-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Caloric Restriction (behavioral)
Hyperglycemic clamp (drug)

Where the study takes place — 1 listed sites

Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics

ClinicalTrials.gov · NCT04466566 · Registry updated: 2026-10-28

Condition / research focus: Healthy
Sponsor: Adrian Vella
Countries with listed sites: United States
Registry dates and results: Start: 2022-10-17. Completion: 2025-12-30 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saline (other)
Exendin-9,39 (biological)
Liraglutide (biological)

Where the study takes place — 1 listed sites

Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Healthy Living BEYOND Weight Study

ClinicalTrials.gov · NCT07075341 · Registry updated: 2026-10-28

Condition / research focus: Overweight or Obesity
Sponsor: American Heart Association
Countries with listed sites: United States
Registry dates and results: Start: 2025-06-30. Completion: 2060-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

None - Observational study (other)

Where the study takes place — 1 listed sites

American Heart Association
Dallas, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion

ClinicalTrials.gov · NCT07398300 · Registry updated: 2026-10-27

Condition / research focus: Type 2 Diabetes; Healhty
Sponsor: Copenhagen University Hospital, Rigshospitalet
Countries with listed sites: Denmark
Registry dates and results: Start: 2026-03-12. Completion: 2027-05 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GIP (drug)
GLP-1 (drug)
Saline (0.9% Sodium Chloride) (other)

Where the study takes place — 1 listed sites

Copenhagen University Hospital - Rigshospitalet
Copenhagen, Denmark
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1RecruitingINTERVENTIONAL

Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib

ClinicalTrials.gov · NCT07782359 · Registry updated: 2026-10-27

Condition / research focus: Lung Cancer
Sponsor: University of Chicago
Countries with listed sites: United States
Registry dates and results: Start: 2026-10-22. Completion: 2030-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Monjouro, Zepbound

Where the study takes place — 1 listed sites

University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial

ClinicalTrials.gov · NCT04535960 · Registry updated: 2026-10-26

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: University Health Network, Toronto
Countries with listed sites: Canada
Registry dates and results: Start: 2019-03-14. Completion: 2021-03-16 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Empagliflozin 25 MG + Liraglutide 1.8 MG (drug) — also listed as: Generic names are above, listed
Liraglutide 1.8 MG + Empagliflozin 25 MG (drug) — also listed as: Generic names are above, listed

Where the study takes place — 1 listed sites

Renal Physiology Laboratory
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

ClinicalTrials.gov · NCT07825857 · Registry updated: 2026-10-26

Condition / research focus: Methamphetamine Use Disorder
Sponsor: University of Texas Southwestern Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2026-10-23. Completion: 2031-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Zepbound, Mounjaro
Placebo (saline) (drug)

Where the study takes place — 4 listed sites

University of Southern California (USC)
Los Angeles, California, United States
Site recruitment: Not yet recruiting
Center of Substance Use and Health
San Francisco, California, United States
Site recruitment: Not yet recruiting
Oklahoma State University (OSU) Center for Health Services
Tulsa, Oklahoma, United States
Site recruitment: Not yet recruiting
UT Southwestern Medical Center
Dallas, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4Not yet recruitingINTERVENTIONAL

Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity

ClinicalTrials.gov · NCT07893457 · Registry updated: 2026-10-26

Condition / research focus: Obese Adults
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2026-10-26. Completion: 2027-10-26 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo (drug)
Tirzepatide (drug) — also listed as: Zepbound

Where the study takes place — 1 listed sites

Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes

ClinicalTrials.gov · NCT07896265 · Registry updated: 2026-10-26

Condition / research focus: Overweight or Obesity Without Diabetes
Sponsor: Regeneron Pharmaceuticals
Countries with listed sites: No country reported
Registry dates and results: Start: 2026-11-18. Completion: 2029-01-23 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Olatorepatide (drug) — also listed as: HS-20094
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

ClinicalTrials.gov · NCT07225829 · Registry updated: 2026-10-23

Condition / research focus: Knee Osteoarthritis; Synovitis of Knee
Sponsor: 4Moving Biotech
Countries with listed sites: Canada · Denmark · France · Poland · Spain · United States
Registry dates and results: Start: 2025-06-17. Completion: 2026-10-19 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

4P004 (drug) — also listed as: Liraglutide
Placebo (NaCl 0.9%) (drug)

Where the study takes place — 22 listed sites

Tucson Orthopaedic Institute
Tucson, Arizona, United States
Site recruitment: Not reported
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
Site recruitment: Not reported
Skylight Health Research Burlington
Burlington, Massachusetts, United States
Site recruitment: Not reported
Durham Bone and Joint Specialists
Ajax, Canada
Site recruitment: Not reported
SJHC London Rheumatology Centre
London, Canada
Site recruitment: Not reported
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc
Québec, Canada
Site recruitment: Not reported
Parker Institute Bispebjerg, Frederiksberg Hospital
Frederiksberg, Denmark
Site recruitment: Not reported
Sanos Clinic Herlev
Herlev, Denmark
Site recruitment: Not reported
CHU Montpellier
Montpellier, France
Site recruitment: Not reported
ChU de Nice
Nice, France
Site recruitment: Not reported
Hôpital Cochin
Paris, France
Site recruitment: Not reported
Hôpital Lariboisière
Paris, France
Site recruitment: Not reported
Centre Hospitalier Universitaire CHU de Reims - Hopital Maison Blanche
Reims, France
Site recruitment: Not reported
Care Access Kraków
Krakow, Poland
Site recruitment: Not reported
Centrum Medyczne Reuma Park
Warsaw, Poland
Site recruitment: Not reported
MICS Centrum Medyczne Warszawa
Warsaw, Poland
Site recruitment: Not reported
Clínica Gaias Santiago
A Coruña, Spain
Site recruitment: Not reported
Complejo Hospitalario Universitario de A Coruna - Hospital Universitario de A Coruna
A Coruña, Spain
Site recruitment: Not reported
HLA Clínica Vistahermosa
Alicante, Spain
Site recruitment: Not reported
Corporacio Sanitaria Parc Tauli - Hospital de Sabadell
Sabadell, Spain
Site recruitment: Not reported
Clinica Nuestra Senora de la Esperanza
Santiago de Compostela, Spain
Site recruitment: Not reported
Hospital Quirónsalud Sagrado Corazón
Seville, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes

ClinicalTrials.gov · NCT04324229 · Registry updated: 2026-10-23

Condition / research focus: Gestational Diabetes
Sponsor: Turku University Hospital
Countries with listed sites: Finland
Registry dates and results: Start: 2020-02-07. Completion: 2025-04-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide 6 MG/ML [Victoza] (drug)
Placebos (drug)

Where the study takes place — 1 listed sites

Turku University Hospital
Turku, Finland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:56 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 1RecruitingINTERVENTIONAL

Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)

ClinicalTrials.gov · NCT07908316 · Registry updated: 2026-11-02

Condition / research focus: Obesity; Overweight
Sponsor: Amgen
Countries with listed sites: United States
Registry dates and results: Start: 2026-11-13. Completion: 2028-02-25 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Maridebart cafraglutide (drug) — also listed as: AMG 133, MariTide

Where the study takes place — 9 listed sites

Arizona Research Center
Phoenix, Arizona, United States
Site recruitment: Recruiting
Catalina Research Institute LLC (CRI) - Montclair
Montclair, California, United States
Site recruitment: Recruiting
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, United States
Site recruitment: Recruiting
AGA Clinical Trials
Hialeah, Florida, United States
Site recruitment: Recruiting
K2 Medical Research Orlando
Maitland, Florida, United States
Site recruitment: Recruiting
The Alliance for Multispecialty Research - Lexington
Lexington, Kentucky, United States
Site recruitment: Recruiting
Alliance for Multispecialty Research - Knoxville
Knoxville, Tennessee, United States
Site recruitment: Recruiting
Fortrea Clinical Research Unit - Dallas
Dallas, Texas, United States
Site recruitment: Recruiting
Fortrea Clinical Research Unit Inc. - Madison
Madison, Wisconsin, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2Not yet recruitingINTERVENTIONAL

Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer

ClinicalTrials.gov · NCT07909889 · Registry updated: 2026-11-02

Condition / research focus: Breast Cancer (Early Breast Cancer); Obesity
Sponsor: Aarhus University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2027-03. Completion: 2029-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (Wegovy®) (drug) — also listed as: Wegovy

Where the study takes place — 2 listed sites

Department of Oncology, Aarhus University Hospital
Aarhus N, Denmark
Site recruitment: Not reported
Department of Oncology, Aarhus University Hospital
Aarhus N, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3Not yet recruitingINTERVENTIONAL

Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea

ClinicalTrials.gov · NCT07846865 · Registry updated: 2026-11-02

Condition / research focus: Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive
Sponsor: Woolcock Institute of Medical Research
Countries with listed sites: Australia
Registry dates and results: Start: 2026-10-01. Completion: 2028-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Continuous Positive Airway Pressure (device)
Tirzepatide (drug)

Where the study takes place — 1 listed sites

Woolcock Institute of Medical Research
Macquarie Park, New South Wales, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2Active, not recruitingINTERVENTIONAL

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT06700538 · Registry updated: 2026-10-30

Condition / research focus: Obesity
Sponsor: Arrowhead Pharmaceuticals
Countries with listed sites: Australia · Canada · Georgia · New Zealand
Registry dates and results: Start: 2024-12-04. Completion: 2028-02-15 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ARO-INHBE (drug)
Placebo (drug)
Tirzepatide (drug)

Where the study takes place — 15 listed sites

Research Site
Camberwell, Australia
Site recruitment: Not reported
Research Site
Charlestown, Australia
Site recruitment: Not reported
Research Site
Maroochydore, Australia
Site recruitment: Not reported
Research Site
Sydney, Australia
Site recruitment: Not reported
Research Site
Chicoutimi, Canada
Site recruitment: Not reported
Research Site
Concord, Canada
Site recruitment: Not reported
Research Site
Toronto, Canada
Site recruitment: Not reported
Research Site
Tbilisi, Georgia
Site recruitment: Not reported
Research Site 2
Tbilisi, Georgia
Site recruitment: Not reported
Research Site
Tbilisi, Georgia
Site recruitment: Not reported
Research Site
Tbilisi, Georgia
Site recruitment: Not reported
Research Site
Grafton, Auckland, New Zealand
Site recruitment: Not reported
Research Site
Auckland, New Zealand
Site recruitment: Not reported
Research Site
Auckland, New Zealand
Site recruitment: Not reported
Research Site
Christchurch, New Zealand
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4Active, not recruitingINTERVENTIONAL

Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

ClinicalTrials.gov · NCT06774079 · Registry updated: 2026-10-29

Condition / research focus: Crohn Disease
Sponsor: University of Miami
Countries with listed sites: United States
Registry dates and results: Start: 2025-03-05. Completion: 2027-03-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)
Mediterranean diet (behavioral)

Where the study takes place — 1 listed sites

University of Miami
Miami, Florida, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients

ClinicalTrials.gov · NCT07728318 · Registry updated: 2026-10-29

Condition / research focus: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Sponsor: Akhtar Saeed Medical and Dental College
Countries with listed sites: No country reported
Registry dates and results: Start: 2027-12-12. Completion: 2028-05-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide + Standard Therapy (Intervention Group) (other)
Standard Oral Antidiabetic Drugs (OADs) (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2Active, not recruitingINTERVENTIONAL

An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder

ClinicalTrials.gov · NCT07693608 · Registry updated: 2026-10-29

Condition / research focus: Obesity; Methamphetamine Use Disorder; Cocaine Use Disorder; Stimulant Use Disorders
Sponsor: University of Texas Southwestern Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2026-08-19. Completion: 2030-03-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)

Where the study takes place — 1 listed sites

UT Southwestern Medical Center
Dallas, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity

ClinicalTrials.gov · NCT07504172 · Registry updated: 2026-10-28

Condition / research focus: Overweight , Obesity; Obesity (Disorder)
Sponsor: Radboud University Medical Center
Countries with listed sites: Netherlands
Registry dates and results: Start: 2026-04-01. Completion: 2026-10-14 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Mounjaro

Where the study takes place — 10 listed sites

NOK clinics
Amsterdam, Netherlands
Site recruitment: Not reported
NOK clinics
Arnhem, Netherlands
Site recruitment: Not reported
NOK clinics
Beverwijk, Netherlands
Site recruitment: Not reported
NOK clinics
Gouda, Netherlands
Site recruitment: Not reported
NOK clinics
Heerlen, Netherlands
Site recruitment: Not reported
NOK clinics
Hoogeveen, Netherlands
Site recruitment: Not reported
NOK clinics
Nieuwegein, Netherlands
Site recruitment: Not reported
NOK clinics
Terneuzen, Netherlands
Site recruitment: Not reported
NOK clinics
The Hague, Netherlands
Site recruitment: Not reported
NOK clinics
Venlo, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Mechanisms of Weight Loss: Tirzepatide vs Semaglutide

ClinicalTrials.gov · NCT07900074 · Registry updated: 2026-10-28

Condition / research focus: Obesity (Disorder)
Sponsor: McMaster University
Countries with listed sites: Canada
Registry dates and results: Start: 2026-10-31. Completion: 2029-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)
Semaglutide (drug)

Where the study takes place — 1 listed sites

McMaster University
Hamilton, Ontario, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2Not yet recruitingINTERVENTIONAL

The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

ClinicalTrials.gov · NCT05499702 · Registry updated: 2026-10-28

Condition / research focus: Type2diabetes
Sponsor: Adrian Vella
Countries with listed sites: United States
Registry dates and results: Start: 2027-12-15. Completion: 2029-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Caloric Restriction (behavioral)
Hyperglycemic clamp (drug)

Where the study takes place — 1 listed sites

Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics

ClinicalTrials.gov · NCT04466566 · Registry updated: 2026-10-28

Condition / research focus: Healthy
Sponsor: Adrian Vella
Countries with listed sites: United States
Registry dates and results: Start: 2022-10-17. Completion: 2025-12-30 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saline (other)
Exendin-9,39 (biological)
Liraglutide (biological)

Where the study takes place — 1 listed sites

Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Healthy Living BEYOND Weight Study

ClinicalTrials.gov · NCT07075341 · Registry updated: 2026-10-28

Condition / research focus: Overweight or Obesity
Sponsor: American Heart Association
Countries with listed sites: United States
Registry dates and results: Start: 2025-06-30. Completion: 2060-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

None - Observational study (other)

Where the study takes place — 1 listed sites

American Heart Association
Dallas, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion

ClinicalTrials.gov · NCT07398300 · Registry updated: 2026-10-27

Condition / research focus: Type 2 Diabetes; Healhty
Sponsor: Copenhagen University Hospital, Rigshospitalet
Countries with listed sites: Denmark
Registry dates and results: Start: 2026-03-12. Completion: 2027-05 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GIP (drug)
GLP-1 (drug)
Saline (0.9% Sodium Chloride) (other)

Where the study takes place — 1 listed sites

Copenhagen University Hospital - Rigshospitalet
Copenhagen, Denmark
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1RecruitingINTERVENTIONAL

Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib

ClinicalTrials.gov · NCT07782359 · Registry updated: 2026-10-27

Condition / research focus: Lung Cancer
Sponsor: University of Chicago
Countries with listed sites: United States
Registry dates and results: Start: 2026-10-22. Completion: 2030-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Monjouro, Zepbound

Where the study takes place — 1 listed sites

University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial

ClinicalTrials.gov · NCT04535960 · Registry updated: 2026-10-26

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: University Health Network, Toronto
Countries with listed sites: Canada
Registry dates and results: Start: 2019-03-14. Completion: 2021-03-16 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Empagliflozin 25 MG + Liraglutide 1.8 MG (drug) — also listed as: Generic names are above, listed
Liraglutide 1.8 MG + Empagliflozin 25 MG (drug) — also listed as: Generic names are above, listed

Where the study takes place — 1 listed sites

Renal Physiology Laboratory
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

ClinicalTrials.gov · NCT07825857 · Registry updated: 2026-10-26

Condition / research focus: Methamphetamine Use Disorder
Sponsor: University of Texas Southwestern Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2026-10-23. Completion: 2031-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Zepbound, Mounjaro
Placebo (saline) (drug)

Where the study takes place — 4 listed sites

University of Southern California (USC)
Los Angeles, California, United States
Site recruitment: Not yet recruiting
Center of Substance Use and Health
San Francisco, California, United States
Site recruitment: Not yet recruiting
Oklahoma State University (OSU) Center for Health Services
Tulsa, Oklahoma, United States
Site recruitment: Not yet recruiting
UT Southwestern Medical Center
Dallas, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4Not yet recruitingINTERVENTIONAL

Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity

ClinicalTrials.gov · NCT07893457 · Registry updated: 2026-10-26

Condition / research focus: Obese Adults
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2026-10-26. Completion: 2027-10-26 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo (drug)
Tirzepatide (drug) — also listed as: Zepbound

Where the study takes place — 1 listed sites

Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes

ClinicalTrials.gov · NCT07896265 · Registry updated: 2026-10-26

Condition / research focus: Overweight or Obesity Without Diabetes
Sponsor: Regeneron Pharmaceuticals
Countries with listed sites: No country reported
Registry dates and results: Start: 2026-11-18. Completion: 2029-01-23 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Olatorepatide (drug) — also listed as: HS-20094
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

ClinicalTrials.gov · NCT07225829 · Registry updated: 2026-10-23

Condition / research focus: Knee Osteoarthritis; Synovitis of Knee
Sponsor: 4Moving Biotech
Countries with listed sites: Canada · Denmark · France · Poland · Spain · United States
Registry dates and results: Start: 2025-06-17. Completion: 2026-10-19 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

4P004 (drug) — also listed as: Liraglutide
Placebo (NaCl 0.9%) (drug)

Where the study takes place — 22 listed sites

Tucson Orthopaedic Institute
Tucson, Arizona, United States
Site recruitment: Not reported
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
Site recruitment: Not reported
Skylight Health Research Burlington
Burlington, Massachusetts, United States
Site recruitment: Not reported
Durham Bone and Joint Specialists
Ajax, Canada
Site recruitment: Not reported
SJHC London Rheumatology Centre
London, Canada
Site recruitment: Not reported
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc
Québec, Canada
Site recruitment: Not reported
Parker Institute Bispebjerg, Frederiksberg Hospital
Frederiksberg, Denmark
Site recruitment: Not reported
Sanos Clinic Herlev
Herlev, Denmark
Site recruitment: Not reported
CHU Montpellier
Montpellier, France
Site recruitment: Not reported
ChU de Nice
Nice, France
Site recruitment: Not reported
Hôpital Cochin
Paris, France
Site recruitment: Not reported
Hôpital Lariboisière
Paris, France
Site recruitment: Not reported
Centre Hospitalier Universitaire CHU de Reims - Hopital Maison Blanche
Reims, France
Site recruitment: Not reported
Care Access Kraków
Krakow, Poland
Site recruitment: Not reported
Centrum Medyczne Reuma Park
Warsaw, Poland
Site recruitment: Not reported
MICS Centrum Medyczne Warszawa
Warsaw, Poland
Site recruitment: Not reported
Clínica Gaias Santiago
A Coruña, Spain
Site recruitment: Not reported
Complejo Hospitalario Universitario de A Coruna - Hospital Universitario de A Coruna
A Coruña, Spain
Site recruitment: Not reported
HLA Clínica Vistahermosa
Alicante, Spain
Site recruitment: Not reported
Corporacio Sanitaria Parc Tauli - Hospital de Sabadell
Sabadell, Spain
Site recruitment: Not reported
Clinica Nuestra Senora de la Esperanza
Santiago de Compostela, Spain
Site recruitment: Not reported
Hospital Quirónsalud Sagrado Corazón
Seville, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes

ClinicalTrials.gov · NCT04324229 · Registry updated: 2026-10-23

Condition / research focus: Gestational Diabetes
Sponsor: Turku University Hospital
Countries with listed sites: Finland
Registry dates and results: Start: 2020-02-07. Completion: 2025-04-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide 6 MG/ML [Victoza] (drug)
Placebos (drug)

Where the study takes place — 1 listed sites

Turku University Hospital
Turku, Finland
Site recruitment: Not reported

Original record, eligibility, contacts and results →